Centro Andaluz de Biología del Desarrollo (CABD)
Centro de investigación
![Foto de Ángel](/img/nophoto.png)
Ángel
Rodríguez Villodres
Publicaciones en las que colabora con Ángel Rodríguez Villodres (11)
2023
-
Role of blaTEM and OmpC in the piperacillin-tazobactam resistance evolution by E. coli in patients with complicated intra-abdominal infection
Journal of Infection, Vol. 87, Núm. 3, pp. 220-229
2022
-
Ultrasensitive and rapid identification of ESRI developer- and piperacillin/tazobactam-resistant Escherichia coli by the MALDIpiptaz test
Emerging Microbes and Infections, Vol. 11, Núm. 1, pp. 2034-2044
2021
-
Impact of the COVID-19 Pandemic on Survival in the Patients With the Intra-Abdominal Infections
Frontiers in Medicine, Vol. 8
-
Semirapid detection of piperacillin/tazobactam resistance and extended-spectrum resistance to b-lactams/b-lactamase inhibitors in clinical isolates of escherichia coli
Microbiology Spectrum, Vol. 9, Núm. 2
2020
-
Antibacterial activity of colloidal silver against gram-negative and gram-positive bacteria
Antibiotics, Vol. 9, Núm. 1
-
Extended-spectrum resistance to β-lactams/β-lactamase inhibitors (ESRI) evolved from low-level resistant Escherichia coli
Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 1, pp. 77-85
-
In vitro effect of ceftazidime-avibactam pressure on ceftazidime-avibactam resistance in KPC-producing Klebsiella pneumoniae clinical isolates
Biosaia: Revista de los másteres de Biotecnología Sanitaria y Biotecnología Ambiental, Industrial y Alimentaria, Núm. 9
-
Repositioning rafoxanide to treat Gram-negative bacilli infections
Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 7, pp. 1895-1905
2019
-
Antibacterial activity of colloidal silver against Gram-negative and Gram-positive bacteria.
Biosaia: Revista de los másteres de Biotecnología Sanitaria y Biotecnología Ambiental, Industrial y Alimentaria, Núm. 8
-
Phylogeny, resistome, and virulome of escherichia coli causing biliary tract infections
Journal of Clinical Medicine, Vol. 8, Núm. 12
2018
-
Heteroresistance to piperacillin-tazobactam in clinical isolates of Escherichia coli sequence type 131
Antimicrobial Agents and Chemotherapy